Drug Profile
Influenza virus vaccine transdermal - Valneva USA
Alternative Names: Influenza vaccine transdermal - Valneva USA; Needle-free influenza patch - Valneva USALatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Iomai Corporation
- Developer Intercell USA
- Class Influenza virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Influenza virus infections
Most Recent Events
- 11 Dec 2017 Intercell USA is now called Valneva USA
- 29 May 2007 Clinical data added to the adverse events and Viral Infections immunogenicity sections
- 17 Jan 2007 Iomai awarded US Department of Health and Human Services contract for the development of a dose-sparing patch for use with a pandemic influenza vaccine